Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
CA 2507532 A1 · Owner: Montana, John Gary · Inventors: Montana, John Gary; Daiss, Jurgen; Fleming, Ian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I) wherein one of X and Y is silicon and the other is , carbon or silicon; Z is oxygen sulphur or -N(R)-, wherein R is hydrogen or alkyl; R1 is hydrogen, halogen, alkyl, alkenyl alkynyl, alkoxy or cycloalkyl; , and R2 is alkyl alkenyl, alkynyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl -alkyl-aryl or -alkyl-, heteroaryl; or a pharmaceutically acceptable salt thereof. The compounds are used in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with GnRH (gonadotropin-releasing hormone) e.g. for the treatment or prevention of progression of cancer (e.g. leukaemia …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 19, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 19, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 19, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.